Amgen Inc.
AMGN
Classifica tra le azioni
#73
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Prezzo delle azioni
$432.40
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$233.77B
Variazione (1 giorno)
-0.38%
Variazione (1 anno)
44.71%
Paese
US
Scambia Amgen Inc. (AMGN)
Categoria
Healthcare
Margine operativo per Amgen Inc. (AMGN)
Margine operativo al October 2026 TTM: 33.18%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Amgen Inc., il margine operativo attuale (TTM) è 33.18%. Alla fine del 2024, il margine operativo era 21.71%.
Storico del margine operativo per Amgen Inc. da 2000 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | 33.18% | -18.11% |
| 2025 | 40.52% | 86.64% |
| 2024 | 21.71% | -22.49% |
| 2023 | 28.01% | -22.92% |
| 2022 | 36.34% | 23.61% |
| 2021 | 29.40% | -18.22% |
| 2020 | 35.95% | -13.19% |
| 2019 | 41.41% | -4.19% |
| 2018 | 43.22% | -0.99% |
| 2017 | 43.65% | 2.46% |
| 2016 | 42.60% | 8.95% |
| 2015 | 39.10% | 26.70% |
| 2014 | 30.86% | -1.75% |
| 2013 | 31.41% | -2.76% |
| 2012 | 32.30% | 16.73% |
| 2011 | 27.67% | -24.89% |
| 2010 | 36.84% | -2.02% |
| 2009 | 37.60% | 8.20% |
| 2008 | 34.75% | 28.99% |
| 2007 | 26.94% | 0.11% |
| 2006 | 26.91% | -31.00% |
| 2005 | 39.00% | 22.91% |
| 2004 | 31.73% | -14.22% |
| 2003 | 36.99% | -360.31% |
| 2002 | -14.21% | -137.27% |
| 2001 | 38.13% | -3.88% |
| 2000 | 39.67% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 49.72% | -98.50% |
US
|
|
| 25.70% | -99.23% |
US
|
|
| 29.32% | -99.12% |
US
|
|
| 26.59% | -99.20% |
CH
|
|
| 16.65% | -99.50% |
US
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.